GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (NAS:ANIK) » Definitions » Total Inventories

Anika Therapeutics (Anika Therapeutics) Total Inventories : $46.4 Mil (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics Total Inventories?

Anika Therapeutics's total inventories for the quarter that ended in Dec. 2023 was $46.4 Mil. Anika Therapeutics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $45.1 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Anika Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $4.41.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Anika Therapeutics's Days Inventory for the three months ended in Dec. 2023 was 247.04.

Inventory Turnover measures how fast the company turns over its inventory within a year. Anika Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.37.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Anika Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 1.05.


Anika Therapeutics Total Inventories Historical Data

The historical data trend for Anika Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Total Inventories Chart

Anika Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.00 46.21 36.01 39.77 46.39

Anika Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.77 41.32 42.60 43.72 46.39

Anika Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Anika Therapeutics  (NAS:ANIK) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Anika Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(72.867+0.75 * 35.961+0.5 * 46.386-58.367
-0-0)/14.66
=4.41

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Anika Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=45.055/16.642*365 / 4
=247.04

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Anika Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=16.642 / 45.055
=0.37

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Anika Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=45.055 / 42.971
=1.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Anika Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics (Anika Therapeutics) Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Anne Nunes officer: SVP, Chief Operations Officer 32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti director 600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran officer: EVP, General Counsel, Corp Sec 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz officer: EVP, CFO, Treasurer C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land director
Stephen Richard director C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop officer: EVP Business Development C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung officer: CFO ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen director 32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower director 32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson director 1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling officer: President 501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767